Antiproton Radiotherapy Peripheral Dose from Secondary Neutrons produced in the Annihilation of Antiprotons in the Target

The AD-4/ACE collaboration studies the biological effects of antiprotons with respect to a possible use of antiprotons in cancer therapy. In vitro experiments performed by the collaboration have shown an enhanced biological effectiveness for antiprotons relative to protons. One concern is the normal tissue dose resulting from secondary neutrons produced in the annihilation of antiprotons on the nucleons of the target atoms. Here we present the first organ specific Monte Carlo calculations of normal tissue equivalent neutron dose in antiproton therapy through the use of a segmented CT-based human phantom. The MCNPX Monte Carlo code was employed to quantify the peripheral dose for a cylindrical spread out Bragg peak representing a treatment volume of 1 cm diameter and 1 cm length in the frontal lobe of a segmented whole-body phantom of a 38 year old male. The secondary neutron organ dose was tallied as a function of energy and organ.